← Evidence map

ArticleClinical journal of gastroenterology2020

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Kazuki Ohya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2020

this papercites it

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. | OpenQuestion